Atomically Precise Gold-Levonorgestrel Nanocluster as a Radiosensitizer for Enhanced Cancer Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31241895.
- Also identified by DOI 10.1021/acsnano.9b03767.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gold nanoclusters have become promising radiosensitizers due to their ultrasmall size and robust ability to adsorb, scatter, and re-emit radiation. However, most of the previously reported gold nanocluster radiosensitizers do not have a precise atomic structure, causing difficulties in understanding the structure-activity relationship. In this study, a structurally defined gold-levonorgestrel nanocluster consisting of Au<sub>8</sub>(C<sub>21</sub>H<sub>27</sub>O<sub>2</sub>)<sub>8</sub> (Au<sub>8</sub>NC) with bright luminescence (58.7% quantum yield) and satisfactory biocompatibility was demonstrated as a nanoradiosensitizer. When the Au<sub>8</sub>NCs were irradiated with X-rays, they produced reactive oxygen species (ROS), resulting in irreversible cell apoptosis. As indicated by <i>in vivo</i> tumor formation experiments, tumorigenicity was significantly suppressed after one radiotherapy treatment with the Au<sub>8</sub>NCs. In addition, compared with tumors treated with X-rays (4 Gy) alone, tumors treated with the nanosensitizer exhibited an inhibition rate of 74.2%. This study contributes to the development of atomically precise gold nanoclusters as efficient radiosensitizers.
Medical subject headings
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Gold
- Levonorgestrel
- Nanoparticles
- Organogold Compounds
- Radiation-Sensitizing Agents